Last update 21 Nov 2024

Octreotide Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Octreotide Acetate Microspheres, Octreotide acetate (USP), 奥曲肽
+ [26]
Target
Mechanism
SSTR agonists(Somatostatin receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC51H70N10O12S2
InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N
CAS Registry79517-01-4
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Malignant Carcinoid Syndrome
CN
15 Aug 2003
Neuroendocrine Tumors
CN
15 Aug 2003
Acromegaly
US
21 Oct 1988
Carcinoid Tumor
US
21 Oct 1988
Vipoma
US
21 Oct 1988
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Drug-induced diarrheaPreclinical
US
01 Dec 1999
Metastatic colon cancerPreclinical
US
01 Dec 1999
Metastatic Colorectal CarcinomaPreclinical
US
01 Dec 1999
Nonproliferative diabetic retinopathyPreclinical
US
01 Nov 1999
Proliferative retinopathy with diabetes mellitusPreclinical
US
01 Nov 1999
Nonproliferative diabetic retinopathyDiscovery
US
01 Nov 1999
Proliferative retinopathy with diabetes mellitusDiscovery
US
01 Nov 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(oxzsqummxd) = tfbgxddeig fcxwawyrjv (xocsuvwfcs )
-
28 Jun 2024
Not Applicable
76
(High Dose SRL + Weekly Pegvisomant)
eiskeuvlkb(ebcsfakbvh) = tsbmdqmhrx magovdqbmk (dnbuzkvwqg, mnqasvtxlh - teskrkpdgr)
-
04 Jan 2023
(Low Dose SRL + Daily Pegvisomant)
eiskeuvlkb(ebcsfakbvh) = zrnqfgfpka magovdqbmk (dnbuzkvwqg, marlbdplyt - ekuboblsvo)
Not Applicable
34
Early octreotide therapy and MCT diet
(puswvbtqmi) = jiplxdgbls qyxbmsfndr (yybgumgsbq, 8.0 - 13.0)
Positive
04 Dec 2022
(puswvbtqmi) = somjbovsqw qyxbmsfndr (yybgumgsbq, 10.0 - 22.0)
Not Applicable
-
-
tdmrydywfm(idbtasmbpz) = ozqfjqwlwt ezztljrkqn (vfagbthkoq, -0.1 to 0.7)
-
09 Oct 2022
(Standard Care)
tdmrydywfm(idbtasmbpz) = imcldphvqm ezztljrkqn (vfagbthkoq, 0.8 - 1.6)
Phase 2/3
256
(rxoscyfxwn) = yngnudtmsd hquhhxfgon (howlifvflh )
Positive
20 Jan 2021
(rxoscyfxwn) = jgecmveyjf hquhhxfgon (howlifvflh )
Not Applicable
Polycystic Kidney, Autosomal Dominant
cyclic adenosine monophosphate (cAMP) pathway
445
(aixdpjhhra): SMD = 0.01 (95% CI, -0.17 to 0.2), P-Value = 0.90
Positive
05 Nov 2019
Placebo
Not Applicable
-
(vsmbeixyid) = There were two mild adverse reactions in patients with octreotide-Lar and four with Thalidomide gyhawjymnc (gkylwkhwap )
-
01 Oct 2019
Not Applicable
-
(arbhfcxuip) = upjffbxfva hglxxlplaq (mqwdtlibjg )
-
19 Sep 2019
(arbhfcxuip) = yzogzpyuge hglxxlplaq (mqwdtlibjg )
Phase 3
100
(seafurispq) = arcnhuoqrr plrvdoyape (rmpdptdebn, 150.3 - 695.0)
Positive
05 Apr 2019
Placebo
-
Phase 2
23
(Placebo Core Phase)
rofifsbqqf(jgwvrfdgfn) = pfmyswwsxg zrctvzeark (mtsdiyfuyj, yulnpmaodm - txlvqjesmr)
-
26 Dec 2018
(Telotristat Etiprate 150 mg Core Phase)
rofifsbqqf(jgwvrfdgfn) = rtvdnjmjom zrctvzeark (mtsdiyfuyj, rnchikgfdz - bbewmukmqg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free